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ABBREVIATIONS
[Ca++]i intracellular free Ca
++ concentration
DMPP 1, 1-dimethyl-4-phenylpiperazinium
EGTA ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid
HEPES N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
PKC protein kinase C
-cPKC conventional PKC isoenzyme; Ca++- and diacylglycerol-dependent
-nPKC novel PKC isoenzyme; diacylglycerol-dependent, Ca++-independent
-aPKC atypical PKC isoenzyme; Ca++- and diacylglycerol-independent
PLA2 phospholipase A2
PLC phospholipase C
-PC-PLC phosphatidylcholine-specific PLC
-PI-PLC phosphatidylinositol-specific PLC
PLD phospholipase D
PMA phorbol-12-myristate-13-acetate (12-tetradecanoylphorbol-13-acetate)
5INTRODUCTION
Tobacco smoking has been an important social habit in American cultures since the
prehistoric era. In the later half of this millennium, tobacco use has spread to nearly
all communities. In addition to smoking, tobacco has been used as chewing tobacco,
and as dry nasal and wetted oral snuff. Among the thousands of chemicals contained
in fermented tobacco products, nicotine is the substance causing addiction (see
Hoffmann and Wynder, 1986).
Besides being a drug of abuse, nicotine is a frequently used model compound in stud-
ies involving cholinergic neurotransmission. The nicotine effects are mediated through
nicotinic acetylcholine receptors that are found both in the periphery and the central
nervous system. Upon binding to its receptor, nicotine opens an integral non-selective
cation channel. This leads to cell depolarisation and induces various responses. Acute-
ly, for example, nicotine evokes transmitter release, while a sustained nicotine expo-
sure upregulates enzymes involved in synthesis of catecholamine transmitters
(Stachowiak et al., 1990).
Nicotine itself is not a major health hazard, but consumption of tobacco, especially
smoking, has often been regarded as the single most important preventable cause of
death and serious diseases (Hoffmann and Wynder, 1986). Thus, alternative ways of
nicotine administration have been developed for smoking cessation. These include
nicotine gum, patches, nasal spray, vapour inhaler, sublingual tablets and lozenges
(Leischow and Cook, 1999).
No matter how nicotine is used, it is metabolised in the body. Cotinine is the major
metabolite of nicotine. It is eliminated much slower than the parent compound, and in
chronic nicotine administration its concentrations are much higher than those of nico-
tine (Benowitz and Jacob, 1999). Cotinine has frequently been considered biologically
inactive (Benowitz, 1996), although some of its effects have been known for nearly four
decades (Borzelleca et al., 1962). Depending on the model, cotinine has caused effects
both similar to and opposite to those of nicotine. Cotinine passes the blood-brain bar-
rier, and thus can participate in the central effects of nicotine administration (Paulson
and Olson, 1995). Only few data on the effects of cotinine at the cellular level have
been published.
Sustained changes in protein phosphorylation status and protein kinase activities can
participate in various events, such as transmitter synthesis (Stachowiak et al., 1990)
and memory formation (Izquierdo, 1994; Micheau and Riedel, 1999). In bovine adrenal
chromaffin cells, nicotine causes a prolonged increase in diacylglycerol levels and pro-
tein kinase C (PKC) activity (Tuominen et al., 1992). The primary catalyst of diglyc-
eride production, phosphatidylinositol-specific phospholipase C (PI-PLC), participates
only in acute responses due to a rapid negative feedback. Thus, the enzymes more
likely responsible for prolonged diacylglycerol production are phosphatidylcholine-spe-
cific phospholipase C (PC-PLC) and phospholipase D (PLD) (Liscovitch, 1992;
Nishizuka, 1995). The existence of the former is uncertain. PLD has also been claimed
to be lacking from bovine chromaffin cells (Purkiss et al., 1991).
In this study, I have used bovine adrenal chromaffin cells as a model of neural cells.
The research focus has been on the role of PLD in nicotinic pharmacology and on the
effects of cotinine on nicotinic responses and cell signalling.
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PHARMACOKINETICS OF NICOTINE AND COTININE
The rewarding effect of nicotine depends on liberation and absorption pharmaco-
kinetics of the dosage form. The more rapidly the brain, or arterial, concentration
peaks, the more intense is the pharmacological response. At physiological pH, approxi-
mately one quarter of nicotine is present in uncharged form and is thus prone to pass
through lipid membranes (Anonymous, 1991; Budavari et al., 1996). Since nicotine is a
base, alkaline tobacco products, such as snuff, chewing tobacco and cigars, favour its
absorption, which has been demonstrated for cigar smoke as compared with cigarette
smoke (Armitage and Turner, 1970).
With cigarette smoking, nicotine reaches the brain in less than 20 seconds, and the
blood nicotine concentration increases for the duration of the smoking period. Use of
oral snuff or chewing tobacco yields peak blood levels comparable with those achieved
by smoking. However, they take approximately half an hour to occur due to thicker
barriers at the site of nicotine absorption (Benowitz et al., 1988). Immediately after
smoking a cigarette, the arterial nicotine concentration is over two-fold higher than
the venous concentration. Nicotine plasma levels in smokers are typically around 200
nM and they never exceed 1 µM (Benowitz and Jacob, 1984; Moreyra et al., 1992;
Gourlay and Benowitz, 1997).
Pharmaceutical preparations used in smoking cessation, including chewing gum,
transdermal patches, sublingual tablets, lozenges and vapour inhalers, release nico-
tine slower than cigarette smoking, thereby avoiding rapid peaks. Nasal spray phar-
macokinetics are somewhat more comparable with smoking. However, no alternative
route of nicotine administration yields as high nicotine peaks as quickly as cigarette
smoking (Benowitz et al., 1988; Mulligan et al., 1990; Hurt et al., 1993, 1998; Gourlay
and Benowitz, 1997; Schuh et al., 1997).
Nicotine is rapidly and widely distributed in the body. It accumulates in the stomach,
bladder, kidneys and salivary glands. Nicotine is eliminated mainly by hepatic meta-
bolism, with a typical elimination half-life of 2 h. Approximately 80 % of nicotine is C-
oxidised, mainly by cytochrome P450 2A6, followed by aldehyde oxidase, yielding coti-
nine. In addition, nicotine may undergo pyrrolidine N-demethylation and N-oxidation,
as well as pyridine N-methylation and N-glucuronidation (Figure 1). One tenth of the
nicotine is excreted as such by the kidneys. As a weak base, nicotine can be trapped in
an acidic environment, and its renal clearance can be enhanced five-fold by urine
acidification (Benowitz et al., 1983, 1994; Anonymous, 1991; Yamazaki et al., 1999).
Cotinine is less lipophilic than nicotine. It distributes to the total body water. Upon ni-
cotine infusion to rats, the highest cotinine concentrations are present in the kidneys,
followed by the lung and the liver. In the brain, the cotinine level somewhat exceeds
the arterial concentration. Interestingly, when cotinine is infused, the tissue cotinine
concentration reaches the arterial concentration only in the kidneys (Gabrielsson and
Bondesson, 1987). Cotinine has been detected in the brain of experimental animals
and in the cerebrospinal fluid of smokers (Paulson and Olson, 1995; Crooks et al.,
1997). However, in a positron emission tomography study, cotinine penetration
through the blood-brain barrier was not observed (Halldin et al., 1992). Yet, the brain
cotinine is probably of peripheral origin, since no evidence for nicotine C-oxidation in
the brain has been found (Hansson and Schmitterlöw, 1965; Crooks et al., 1997).
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FIGURE 1. The main metabolic pathways of nicotine. The relative amount of the metabolites in the urine
is displayed as percentages.
Cotinine is eliminated relatively slowly with a typical half-life of 15 – 20 h (Benowitz
et al., 1983; Curvall et al., 1990). In the venous blood of smokers, the steady-state coti-
nine concentration is higher than the peak nicotine concentration, typically 3 – 4 µM
(Benowitz et al., 1983; Benowitz and Jacob, 1994). Cotinine is not a metabolic end pro-
duct (Figure 1). One sixth is excreted in the urine as such, and the rest is metabolised
in the liver via both the phase I functionalisation reactions and the phase II conjuga-
tion reactions. At least pyridine N-methylation, N-glucuronidation and N-oxidation,
hydroxylation of the pyrrolidine ring at two different sites, and pyrrolidine N-de-
methylation are known to occur (Byrd et al., 1992; Benowitz et al., 1994). Due to its
relatively slow elimination and tendency to accumulate, cotinine could affect biological
systems if it possessed even minor affinity for nicotinic receptors.
NICOTINIC ACETYLCHOLINE RECEPTORS AND THEIR LIGANDS
RECEPTORS
Studies of nicotine effects on muscle led John Newport Langley to suggest the exis-
tence of a receptive substance nearly one hundred years ago (Langley, 1905). Later,
the nicotinic receptor was the first to be sequenced, cloned and gene-sequenced (Noda
et al., 1982, 1983a, 1983b; Claudio et al., 1983). Assistance in reaching these mile-
stones was provided by the electric eel Electrophorus and the electric ray Torpedo spe-
cies, whose electric organs  express a large number of nicotinic acetylcholine receptors.
Furthermore, the electric organ nicotinic receptor protein was relatively easy to purify
by affinity chromatography utilising α-bungarotoxin (see Lindstrom, 1999).
The nicotinic acetylcholine receptors are pentameric ion channels. Each of the sub-
units spans the membrane four times and all subunits contribute to channel forma-
tion. To date, genes encoding 16 different subunits of the vertebrate nicotinic receptors
have been cloned. These subunits are identified as α1 – α9, β1 – β4, γ, δ and ε. The
subunits present in adult neuromuscular junction are α1, β1, ε and δ. In the foetal
muscle, γ subunit replaces ε, as is also the case in electric organs. Outside the neuro-
muscular junction, α2 – α6 and β2 – β4 are thought to form the heteropentameric re-
ceptors with both α and β subunits. Subunits α7 – α9 form the usually homomeric
non-β receptors. The heteropentameric neuronal receptors are frequently presented as
8consisting of two α and three β subunits. However, neither the subunit stoichiometry
nor the arrangement of most of the receptors are known with certainty. Furthermore,
it is unclear whether all subunits are naturally expressed in functional combinations
(see Sargent, 1993; McGehee and Role, 1995; Lukas et al., 1999). Besides the central
and the peripheral nervous systems and sensory organs, neuronal nicotinic receptors
are reportedly expressed in lymphocytes, granulocytes, fibroblasts, chondrocytes,
spermatozoa, placenta and pulmonary neuroendocrine cells (see Lukas et al., 1999).
The nomenclature of nicotinic acetylcholine receptors has not been established. The
historical classification of nicotinic receptors to neuronal (ganglionic-type, C6, NN, N1)
and muscle (C10, NM, N2) receptors (Watson and Girdlestone, 1993) ceased nearly a
decade ago. After that, various terms have been used to identify receptor types
(Watson and Girdlestone, 1995; Watling, 1998; Alexander and Peters, 1999). Reflect-
ing the difficulty of creating a satisfying nomenclature, the IUPHAR compendium of
receptor classification provides no information on nicotinic acetylcholine receptor
(IUPHAR Committee on Receptor Nomenclature and Drug Classification, 1998). Re-
cently, however, the subcommittee on nicotinic acetylcholine receptors has recommen-
ded a classification based on the subunits forming the receptors (Lukas et al., 1999).
The subunit types and their stoichiometry are expressed if known. If only some of the
subunits forming the receptor in question are known, the identified subunits are
enumerated and an asterisk added to indicate that additional subunit types may exist.
According to the recommended classification, the adult muscle nicotinic acetylcholine
receptor type is (α1)2β1εδ, and the foetal muscle and electric organ receptor type is
(α1)2β1γδ. Autonomic ganglion receptors may be called α3α5β2β4, α3α5β4, α3β4,
α3β4*, α3* or α7* receptors, depending on their composition. In the central nervous
system, the major combination is (α4)2(β2)3, and other receptors expressed include
α4α5β2, α7* and α9* receptors. In the cerebellum, α3β2β3β4 and α3β2β4β5 combina-
tions have also been demonstrated. The α8 subunit is expressed in avian retinas, and
hitherto has only been observed in chicks.
AGONISTS
The natural ligand of nicotinic receptors is acetylcholine. Other agonists include nico-
tine, 1,1-dimethyl-4-phenylpiperazinium (DMPP), cytisine, epibatidine and numerous
novel ligands developed by the pharmaceutical industry. However, many of the com-
pounds regarded as agonists are partial agonists in certain models. Indeed, despite
being called nicotinic receptors, many of the natural receptors respond to nicotine as
to a partial agonist. Properties of selected nicotinic agonists are presented in Table 1.
The clinical use of nicotine has been limited to treating withdrawal symptoms upon
smoking cessation. In the near future, nicotinic agonists may get new clinical indica-
tions. Thus far, they have proven effective in preclinical or early clinical studies for re-
lieving pain and cognitive disorders, as well as symptoms of parkinsonism, Tourette's
syndrome and schizophrenia (see Decker and Arneric, 1999; Donnelly-Roberts and
Brioni, 1999; Flores and Hargreaves, 1999; Leonard et al., 1999; Levin et al., 1999;
Menzaghi et al., 1999).
In receptor-binding studies utilising various nicotinic receptor agonists, both apparent
one-site binding and apparent two-site binding have been reported. The high-affinity
binding is considered to represent ligand binding to the desensitised receptors, while
the low-affinity binding occurs at the ground-state receptors. Nevertheless, the differ-
9ent binding affinities may also represent different receptor populations. Mathematical
modelling of the binding data is further complicated by the fact that opening of a cho-
linergic receptor channel requires binding of two agonist molecules to the pentamer
and that the agonist sites may cooperate (see Haylett, 1996; Gotti et al., 1997).
TABLE 1. Characteristics of nicotinic acetylcholine receptor agonists
Ligand (source) Affinity for receptors a References  b  
A-85380 rat forebrain: Ki 97 pM Xiao et al., 1998
ABT-418 brain heteropentameric: Ki 3 nM Arneric et al., 1994
acetylcholine (endogenous) Ki: α2β2: 2 nM, α3β2 & α4β2: 30 nM, α4β4: 70
nM, α2β4 100 nM, α3β4: 560 nM
Parker et al., 1998
anabaseine (Aphaenogaster
sp. ant; Paranemertes sp.
worm)
Ki: α7: 32 nM, α4β2: 32 nM, fish muscle: 210
nM
Kem et al., 1997
anabasine (tobacco) Ki: α2β2: 14 nM, α3β2: 57 nM, α7: 58 nM,
α4β2: 76–260 nM, α4β4: 370 nM, α2β4: 450
nM, α3β4: 2.1 µM, fish muscle: 7.2 µM
Kem et al., 1997; Parker
et al., 1998
anatoxin-a (cyanobacterium
Anabaena flos-aquae)
Ki: rat forebrain 6.5 nM, α3β4: 53 nM Thomas et al., 1993; Xiao
et al., 1998
carbachol Ki: rat forebrain 428 nM, α3β4: 3.8 µM;
resistant to cholinesterase
Xiao et al., 1998
choline (endogenous) α4β2:Ki 110 µM but induces no current; α7: full
agonist with 2.3 mM EC50 (current)
Papke et al., 1996;
Alkondon et al., 2000
cytisine (e.g. Laburnum
anagyroides)
Ki: α2β2: 380 pM, α4β2: 990 pM, α4β4: 1.2 nM,
α2β4: 4.9 nM, α3β2: 14 nM, α3β4: 56–200 nM;
weak at bovine β4
Campos-Caro et al., 1997;
Parker et al., 1998; Xiao
et al., 1998
dimethylaminocinnamylidine Ki: α7: 34 nM, α4β2: 350 nM de Fiebre et al., 1995
DMPP Ki: β2-containing: 10–50 nM, β4-containing: ca.
1 µM; guanethidine-like activity
Birmingham and Wilson,
1965; Parker et al., 1998
epibatidine (frog Epipedobates
tricolor)
Ki: neuronal heteropentameric: picomolar,
muscle & α7: 1–10 nM
Badio and Daly, 1994;
Gerzanich et al., 1995
GTS-21 α7-selective partial agonist: Ki 310 nM, EC50
ca. 100 µM (current); has an active metabolite
Meyer et al., 1998
lobeline (tobacco) Ki: α2β2: 2.6 nM; α4β2: 4 nM; α3β2: 13 nM;
α4β4: 49 nM; α2β4: 220 nM; α3β4: 480 nM
Damaj et al., 1997;
Parker et al., 1998
nicotine (tobacco) Ki: α2β2: 800 pM; α4β2: 4–5 nM; α3β2: 16 nM;
α4β4: 26 nM; α2β4: 70 nM; α3β4: 300–500 nM;
α7: 400 nM; fish muscle: 1.4 µM
Kem et al., 1997; Parker
et al., 1998; Xiao et al.,
1998
RJR-2403 Ki: α4β2: 26 nM, α7: 36 µM Bencherif et al., 1996
SIB-1508Y neuronal, weak at α3β4, inactive at α7; rat
brain estimated Ki 3–10 nM
Cosford et al., 1996
SIB-1553A prefers β4; in rat brain estimated Ki 0.3–1 µM Vernier et al., 1999
SIB-1765F α4β2-selective; Ki: α4β2: 7.5 nM, α4β4: 235 nM Sacaan et al., 1997
tetramethylammonium Ki: α4β2: 260–480 nM Papke et al., 1996;
Whiteaker et al., 1998
aEC50: concentration causing half-maximal stimulation (studied parameter in parentheses)
bGeneral references: (McGehee and Role, 1995; Vizi et al., 1995; Adams and Swanson, 1996; Budavari et
al., 1996; Gotti et al., 1997; Alexander and Peters, 1999)
ANTAGONISTS
As with most receptors and receptor families, several antagonists recognise closely
related receptors with different affinities. However, most of the nicotinic acetylcholine
receptor subtypes lack highly selective antagonists. Nicotinic antagonists may block
the acetylcholine binding site, they may affect the agonist affinity state of the recep-
tor, or they may block the integral ion channel itself (Alexander and Peters, 1999).
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Since development of various antihypertensive agents by the pharmaceutical industry,
neuronal nicotinic antagonists have not been used much in clinical practice. However,
promising results have been obtained in relieving Tourette's syndrome with mecamyl-
amine (Sanberg et al., 1998), and muscle nicotinic receptor antagonists such as rocuro-
nium, vekuronium and mivacurium, are used in anaesthetic practice to sustain skele-
tal muscle relaxation. Despite their limited used in humans, neuronal nicotinic recep-
tor antagonists are important tools in pharmacological and toxicological research.
Properties of selected nicotinic antagonists are listed in Table 2.
TABLE 2. Characteristics of nicotinic antagonists
Ligand (source)  Affinity for receptors a References  b  
atropine (Atropa belladonna) α9: IC50 1.3 µM (10 µM acetylcholine) Elgoyhen et al., 1994
α-bungarotoxin (krait Bungarus
multicinctus)
IC50: muscle, α7, α8, α9: 0.5 – 10 nM;
inactive at neuronal heteromers
Motomura et al., 1992;
López et al., 1998
κ-bungarotoxin (B. multicinctus) Ki: α3β2: 10 nM; muscle, α3β2: low
micromolar
Luetje et al., 1990
chlorisondamine (synthetic) neuronal channel blocker: micromolar El-Bizri and Clarke, 1994
α-conotoxins GI, GIA, GII, MI,
SI, SIA, SII (snails Conus spp.)
muscle: IC50 10 – 100 nM (100 and 500
nM acetylcholine)
Luetje et al., 1990; Johnson
et al., 1995
α-conotoxin IMI (C. imperialis) IC50: α7: 0.22 µM (500 µM acetylcholine);
α9: 1.8 µM (100 µM acetylcholine)
Johnson et al., 1995
α-conotoxin MII (C. magus) IC50: α3β2 0.5 nM (300 µM acetylcholine) Cartier et al., 1996
decamethonium (synthetic) IC50 micromolar, weak partial agonist
dihydro-β-erythroidine (seeds of
Erythrina spp.)
Ki: α3β4: 220 µM; rat brain: 29 µM Xiao et al., 1998
gallamine (synthetic) brain: Ki ca. 100 µM; muscle IC50 8 µM
(electrical stimulation)
Törocsik et al., 1989;
Fletcher and Steinbach,
1996
hexamethonium (synthetic) neuronal channel blocker; α3β4: IC50 ca.
200 µM (100 µM nicotine)
Xiao et al., 1998
histrionicotoxin (frog
Dendrobates histrionicus)
IC50: α3β4*: 3 µM (0.3 mM carbachol);
muscle: micromolar
Wada et al., 1989
lophotoxin (corals Lophogorgia
spp.)
Ki: muscle, β2-containing receptors: ca.
10 µM; irreversible
Luetje et al., 1990
mecamylamine (synthetic) β4-containing receptors IC50 ca. 1 µM (20
– 200 µM nicotine); channel blocker
Stauderman et al., 1998;
Xiao et al., 1998
methyllycaconitine (Delphinium
brownii seeds)
Ki: α7: ca. 1 nM; neuronal: 4–6 µM Ward et al., 1990; Whiteaker
et al., 1998
muscarine (mushrooms Clitocybe
spp., Inocybe spp. )
α9: IC50 75 µM (10 µM acetylcholine) Elgoyhen et al., 1994
neosurugatoxin (Japanese ivory
mollusc Babylonia japonica)
IC50: α3β4*: 27 nM (0.3 mM carbachol);β2-containing receptors: low nanomolar;
muscle: ca. 100 nM (100 nM ACh)
Wada et al., 1989; Luetje et
al., 1990
nereistoxin (annelid
Lumbriconereis heteropoda)
muscle, neuronal; chick retina: IC50 3.5
µM (0.3 mM DMPP)
Xie et al., 1993; Xie et al.,
1996
nicotine (tobacco) IC50: α9: 30 µM (10 µM acetylcholine) Elgoyhen et al., 1994
strychnine (nut Strychnos nux-
vomica)
IC50: α9: 20 nM (10 µM acetylcholine);
muscle,α2β2, α2β4: micromolar
Elgoyhen et al., 1994;
García-Colunga and Miledi,
1999
tubocurarine (Chondodendron
tomentosum stems)
muscle, neuronal: Ki micromolar Xiao et al., 1998
aIC50: concentration causing half-maximal inhibition (stimulus in parentheses)
bGeneral references: (Deneris et al., 1991; McGehee and Role, 1995; Vizi et al., 1995; Adams and
Swanson, 1996; Budavari et al., 1996; Gotti et al., 1997; Alexander and Peters, 1999)
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NICOTINE SIGNALLING
Nicotinic acetylcholine receptors are ligand-gated cation channels. Binding of two
agonist molecules on the pentamer stabilises the channel open-state. The activated
receptors non-selectively conduct cations. The overall conductance as well as the
relative conductances of various ions depend on the subunit composition of the
receptor (see Lindstrom et al., 1995; McGehee and Role, 1995; Ramirez-Latorre et al.,
1999). Receptor-carried Ca++ alone may increase the intracellular free Ca++ concentra-
tion ([Ca++]i) sufficiently to evoke responses (Zhou and Neher, 1993). However, usually
membrane depolarisation and a secondary Ca++ influx through voltage-operated chan-
nels follow nicotinic activation.
A rapid increase in [Ca++]i activates various intracellular processes, such as trans-
mitter and neuropeptide release and activation of phospholipase A2 (PLA2). The events
are not unique to nicotinic stimulation, but occur upon membrane depolarisation in
general (Livett et al., 1981; Holz et al., 1982; Frye and Holz, 1984). The rapid increase
in [Ca++]i also activates phospholipase C (PLC), generating diacylglycerol which, in
turn, activates PKC (TerBush and Holz, 1986; Eberhard and Holz, 1987; TerBush et
al., 1988). Despite generally being accompanied and modulated by kinase activation,
transmitter exocytosis can also occur in its absence (TerBush and Holz, 1990).
The agonists act not only by stabilising the receptor open-state thus causing activa-
tion, but also by evoking desensitisation. Desensitisation, by definition, refers to a
situation, where the decline in response, either fade or tachyphylaxis, involves the
receptor itself or is a direct consequence of receptor activation (Jenkinson et al., 1998).
Although nicotinic receptors may be in several un-, mono- and diliganded
conformations, relatively simple models on activation-desensitisation cycles can be
presented due to the low probability of certain conformational changes (Katz and
Thesleff, 1957; Auerbach and Akk, 1998). The desensitisation is mainly thought to
occur in diliganded state, and the recovery through ligand dissociation (Figure 2).
RC RA2C RA2
RCD RD RA2D
FIGURE 2. A two-gate model of nicotinic receptor
activation and desensitisation (Auerbach and
Akk, 1998). R represents the receptor and A2 the
two bound agonists. C and D represent the closed
states of the putative activation and desensitisa-
tion gates. Thus, the ion channel is conductive on-
ly in conformation RA2. No monoliganded states
are presented because of their low probability of
undergoing desensitisation or recovering from it.
Desensitisation also seems to occur without a preceding activation, not in full agree-
ment with the simplified models. The receptor function is frequently desensitised at a
lower concentration than that required for activation, in particular during prolonged
exposures. Thus, whether a nicotinic agonist evokes or inhibits cholinergic responses
depends not only on the subunit composition of the receptor in question, but also on
the length of the exposure and the concentration of the agonist (Riker, 1968; Marks et
al., 1996; Marks, 1999). Indeed, the nicotine concentrations reached while smoking
more closely resemble receptor-desensitising concentrations than activating concen-
trations. Thus, it is tempting to believe that at least some of the common nicotine
effects would be mediated by receptor desensitisation instead of activation. This is
supported by the ability of mecamylamine to relieve symptoms of Tourette's
syndrome.
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SIGNALLING THROUGH PHOSPHOLIPASE C AND PHOSPHOLIPASE D
Phospholipases are enzymes that hydrolyse ester bonds of various phospholipids. The
mammalian phospholipases are PLA2, PLC and PLD, which are named after the
linkages they cleave (Figure 3A). The primary glycerol-based products of PLC and
PLD, diacylglycerol and phosphatidic acid, can be interconverted by diacylglycerol
kinase and phosphatidic acid phosphohydrolase (Figure 3B).
FIGURE 3. A: Bonds hydrolysed by phospholipases A2 (PLA2), C (PLC) and D (PLD).  R1 and R2 represent
esterified fatty acids, e.g. oleic, palmitic, or arachidonic acid. R3 represents the polar head of the
phospholipid, e.g. choline or inositol 4,5-bisphosphate. B: Interconversion of phosphatidic acid (PA), and
diacylglycerol (DG), generated by PLD and phosphatidylinositol-specific PLC (PI-PLC). DGK: diacyl-
glycerol kinase; PAP: phosphatidic acid phosphohydrolase; PC: phosphatidylcholine; PI-4,5-P2:
phosphatidylinositol 4,5-bisphosphate; I-1,4,5-P3: insitol-1,4,5-trisphosphate.
PHOSPHOLIPASE C
PLC can be divided into two major categories according to substrate specificity: PI-
PLC and PC-PLC. PI-PLC is divided into PLCβ, PLCγ and PLCδ subclasses, all of
which have isoenzymes identified by Arabic numerals (see Singer et al., 1997; Bairoch
and Apweiler, 1999). Although mammalian PC-PLC has not been cloned, an abun-
dance of data suggests its existence (Cook and Wakelam, 1992; Nofer et al., 1997).
PLCβ and PLCδ enzymes are regulated by heterotrimeric G proteins. In the classical
activation pathway, PLCβ  interacts with the α subunits of Gq proteins (Smrcka et al.,
1991; Hepler et al., 1993). In addition, the G protein βγ subunits stimulate PLCβ, al-
beit not as effectively as the α subunits (Hepler et al., 1993; Gudermann et al., 1996).
PLCδ is stimulated by the α subunits of Gh proteins (Feng et al., 1996), whereas PLCγ
is activated by growth factors probably via tyrosine phosphorylation (see Singer et al.,
1997; Lymn and Hughes, 2000).
Inositol lipid hydrolysis can be stimulated by increasing [Ca++]i, without prior activa-
tion of G-protein-coupled or tyrosine kinase receptors (Eberhard and Holz, 1987,
1991). Although inositol lipids are required for Ca++-stimulated exocytosis, PI-PLC
activity and hydrolysis are not necessary (Eberhard et al., 1990).
In addition to diacylglycerol, which activates the conventional and novel PKC
isoenzymes (see below), PI-PLC activity yields inositol 1,4,5-trisphosphate. It acts on
specific endoplasmic reticular receptors, thus evoking Ca++ release. Ca++, in turn, is an
PC PI-4,5-P2
choline PA DG I-1,4,5-P3
PLD PI-PLC
PAP
DGK
H2C–O–C–R1
HC–O–C–R2
H2C–O–P–O–R3
O
O
O
O
A B
PLC PLD
PLA2
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important intracellular messenger affecting transmitter release and the recovery of
nicotinic receptors from desensitisation, as well as the activity of various other ion
channels and enzymes (see Berridge, 1993; Fenster et al., 1999).
Stimulation of PLCβ-linked receptors leads to a biphasic diglyceride production. While
the early phase is accompanied by inositol trisphosphate formation, the later phase is
not, suggesting that PI-PLC activation is transient (Griendling et al., 1986; Wright et
al., 1988; Fukami and Takenawa, 1989). Sustained diglyceride formation can be cata-
lysed by a sequential action of PLD and phosphatidic acid phosphohydrolase
(Martinson et al., 1990), or by a putative PC-PLC (Cook and Wakelam, 1992). Further-
more, a direct PKC activation by phorbol esters or synthetic diglycerides inhibits the
early phase of diglyceride formation by PLCβ, without affecting the later phase
(Griendling et al., 1986; Portilla et al., 1988; Tilly et al., 1990).
PHOSPHOLIPASE D
PLD activity was initially observed in plants more than fifty years ago. Nearly thirty
years later, it was detected in mammalian tissues, first in the rat brain (Saito and
Kanfer, 1975). Thereafter, PLD has been demonstrated in virtually all mammalian
cells and tissues studied (Meier et al., 1999). Bovine adrenal chromaffin cells have
been claimed to be an exception, and whether they possess PLD activity is under de-
bate (Purkiss et al., 1991; García et al., 1992; Caumont et al., 1998; Glenn et al., 1998).
The first mammalian PLD was cloned and characterised relatively late (Hammond et
al., 1995). The enzyme exists in two alternatively spliced forms, PLD1a and PLD1b
(Hammond et al., 1997). A distinct PLD isoenzyme, PLD2, has also been cloned. It is
constitutively active and appears to be regulated mainly by inhibition (Colley et al.,
1997; Kodaki and Yamashita, 1997). There is also evidence suggesting that at least
one more type, dependent on oleic acid but independent of phosphoinositides, remains
to be cloned (Massenburg et al., 1994; Okamura and Yamashita, 1994; Frohman et al.,
1999). Some structural and regulatory properties of cloned PLDs and oleate-depen-
dent PLD activity are summarised in Table 3.
TABLE 3. Characteristics of phospholipase D enzymes and activities
PLD1a, PLD1b PLD2 Oleate-dependent PLD
Size 124 kDa (a), 119 kDa (b) 106 kDa 190 kDaa
Preferred
membranes
Golgi membranes,
microsomes, endosomes
plasma membrane plasma membrane,
nucleus, microsomes
Cytosolic probably possibly no
Basal activity low high low
Activation by
*lipids PIP2, PIP3b PIP2, PIP3 oleate, arachidonate
*GTPases Arf, RhoA, Rac, Cdc42 minorc no
*kinases cPKCα, β; nPKCε no no
Inhibitory proteins synaptojanin, fodrin, AP3 synaptojanin, synuclein not known
Other inhibitors oleate, primary alcohols,
ceramides
oleate, primary alcohols primary alcohols
References: (Okamura and Yamashita, 1994; Col-
ley et al., 1997; Exton, 1997; Hammond et al.,
1997; Kodaki and Yamashita, 1997; Morris et al.,
1997b; Brown et al., 1998; Katayama et al., 1998;
Lopez et al., 1998; Frohman et al., 1999; Houle
and Bourgoin, 1999)
asize approximated from electrophoresis gels
bPIP2: phosphatidylinositol 4,5-bisphosphate,
PIP3: phosphatidylinositol 3,4,5-trisphosphate
cArf reportedly activates a truncated PLD2
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A full activation of PLD1 requires the presence of Arf, RhoA, active PKC and inositol
phospholipids. However, neither phosphorylation nor phosphoinositidase activity is
necessary. Since the effects of the above-mentioned activators are synergistic, it is
probable that each has a separate regulatory binding site on the enzyme (see Singer et
al., 1996, 1997; Morris et al., 1997b).
A number of extracellular signals that act through tyrosine kinase receptors or Gq fa-
mily proteins and PKC, increase PLD activity. Examples include angiotensin II, bra-
dykinin, choline esters, insulin, and phorbol esters (Qian and Drewes, 1989; Horwitz,
1991; Purkiss et al., 1991; Horwitz and Ricanati, 1992; Kanoh et al., 1992; Standaert
et al., 1996; Jung et al., 1998). Effects of nicotinic agonists and cell depolarisation by
high extracellular potassium on PLD activity are less clear (Caumont et al., 1998;
Glenn et al., 1998; Singh et al., 1998).
PLD and PLD-produced phosphatidic acid have been suggested to have a role in va-
rious phenomena. Clearly, PLD alters membrane composition and physical properties
by hydrolysing phosphatidylcholine to phosphatidic acid. The released choline is not
known to serve intracellular signalling functions, but can be used as a substrate in
acetylcholine synthesis. PLD has a role in exocytosis for example from neutrophils and
mast cells, but it does not appear to be necessary for the process in all cell types
(Glenn et al., 1998; Jones et al., 1999). Importantly, diglyceride generation from phos-
phatidic acid by phosphatidic acid phosphohydrolase may in part be responsible for
sustained PKC activation (Liscovitch, 1992; Nishizuka, 1995). PLD and phosphatidic
acid have a mitogenic effect on multiplying cells (Boarder, 1994; Venable and Obeid,
1999). Phosphatidic acid may also directly participate in PKC activation, and may en-
hance the receptor-mediated PLC activation (see English et al., 1996). Furthermore, it
selectively activates a putative dual specificity protein kinase (McPhail et al., 1999).
Phosphatidic acid can be converted to lysophosphatidic acid by PLA2 to stimulate cell
proliferation, tissue regeneration and transmitter release via Gq- and Gi-coupled
receptors and to enhance PKC activation (see Moolenaar, 1995; Nishizuka, 1995).
CALCIUM SIGNALLING
In resting cells, the [Ca++]i is usually around or below 100 nM. Plasma membrane and
smooth endoplasmic reticulum Ca++ pumps, plasma membrane Na+/Ca++ antiporter as
well as mitochondrial Ca++ carriers extrude Ca++ from the cytosol and hence partici-
pate in sustaining the low [Ca++]i and terminating Ca
++ signals (Alberts et al., 1994).
Various mechanisms are involved in the entry of extracellular Ca++ into the cytosol.
Ca++ may enter a cell through Ca++-carrying transmitter receptors, such as nicotinic
acetylcholine receptors and NMDA glutamate receptors. Store-operated Ca++ channels
are opened in response to emptied intracellular Ca++ stores, and they are responsible
for capacitative calcium entry. The mechanism is unknown, but protein-protein inter-
actions may be involved (Berridge et al., 1998). Voltage-operated Ca++ channels are
opened upon membrane depolarisation. They are classified according to activation
threshold, kinetics, conductivity and pharmacology to L-, T-, N-, P-, Q- and R-type
channels. The L- and T-type channels are found in several cell types while the rest of
the channel types appear neuronal (see Trist and Spedding, 1998; Watling, 1998).
Ca++ may be released to the cytosol also from endoplasmic reticular stores. Two recep-
tor-operated release pathways are known. Inositol 1,4,5-trisphosphate receptors are
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activated by PLC-generated inositol 1,4,5-trisphosphate. Ryanodine receptors are acti-
vated by caffeine, ryanodine and their putative physiological agonist cyclic adenosine
diphosphate ribose. These endoplasmic reticular receptors are sensitised by Ca++, and
they mediate calcium-induced Ca++ release (Berridge, 1998).
Changes in the [Ca++]i are detected by various proteins including calmodulin, troponin
C, annexins, cPKCs and ion channels. Hence, it regulates a multitude of cell events
from fertilisation to cell death. It is a crucial relay pathway controlling cytoskeletal
organisation, contraction, secretion including transmitter release, many metabolic
functions, proliferation and apoptosis (see Berridge et al., 1998).
PROTEIN KINASE C
REGULATION
PKC was originally identified as a proteolytically activated protein kinase with no ob-
vious function in signal transduction (Inoue et al., 1977; Takai et al., 1977). Soon it
was realised that it was a calcium-activated enzyme with absolute phospholipid de-
pendence and great diacylglycerol sensitivity (for early reviews, see Nishizuka, 1984,
1986). After less than a decade, however, it became evident that PKC is not a single
entity, but rather a family of serine-threonine kinases (Coussens et al., 1986; Parker et
al., 1986). Moreover, calcium- and diglyceride-independent isoenzymes were detected
(Ohno et al., 1988; Ono et al., 1988, 1989; Schaap et al., 1989). Indeed, the differences
in activation requirements have led to confusions in nomenclature. Upon uncovering
the structure and basic biochemistry of mouse PKCµ, it was first named protein
kinase D (Valverde et al., 1994), and even today both of these names are used.
In mammals, eleven protein kinase C isoenzymes have been identified (Bairoch and
Apweiler, 1999). The conventional isoenzymes (cPKCα, -β1, -β2 and -γ) require Ca++
and diacylglycerol for activation. The novel isoenzymes (nPKCδ, -ε, -η, -θ and -µ) are
Ca++-independent but still diacylglycerol-dependent. The atypical isoenzymes (aPKCζ
and -ι) need neither diglyceride nor Ca++ for activation. Conventional PKCβ1 and -β2
are alternative splicing products of a single gene, while distinct genes code the rest of
the isoenzymes (Mellor and Parker, 1998; Ron and Kazanietz, 1999).
In addition to the conventional lipid regulators of PKC, namely phosphatidylserine
and diacylglycerols, free cis-unsaturated fatty acids and some phosphatidylcholine
species have an activity-enhancing effect on cPKC isoenzymes (Shinomura et al., 1991;
Burns and Bell, 1992; Ron and Kazanietz, 1999). Phosphatidylinositol 3,4-bisphos-
phate and phosphatidylinositol 3,4,5-trisphosphate activate the n- and aPKCs
(Nakanishi et al., 1993; Singh et al., 1993). Phosphatidic acid and ceramide can also
activate aPKCζ (English et al., 1996; Galve-Roperh et al., 1997; Wang et al., 1999).
In the resting state, PKC is cytosolic and a pseudosubstrate domain occupies the cata-
lytic site. Upon enzyme activation, Ca++ permits cPKC isoenzymes to associate with
membranes. The membrane-associated PKC is then inserted into the membrane, the
pseudosubstrate leaves the catalytic site and the kinase is activated. Diacylglycerol is
required for membrane insertion of c- and nPKCs. Activation of aPKCs is less well un-
derstood (Burns and Bell, 1992; Keranen and Newton, 1997; Ron and Kazanietz,
1999).
A great number of stimuli, especially those acting through receptors coupled to PLC
and phosphatidylinositol bisphosphate hydrolysis, transiently activate PKC. PKC is
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also the major receptor for tumour-promoting phorbol esters which bind to the digly-
ceride site of the enzyme (see Parker, 1992). A prolonged increase in the membrane-
bound, i.e. the active, PKC accompanied with an increased level of diglycerides can be
evoked by phorbol esters and by the cell membrane receptor agonists nicotine and
angiotensin II (Tuominen et al., 1991; Tuominen et al., 1992; Tuominen et al., 1993).
Phorbol esters not only activate PKC, but upon prolonged exposure, they cause down-
regulation of PKC protein and activity (Rodriguez-Pena and Rozengurt, 1984). This is
due to increased proteolysis of the membrane-associated enzyme by proteases, such as
calpain. Initially, a constitutive kinase activity is generated as the regulatory lipid-
binding domain is separated from the catalytic one. However, the final net effect is a
reduced PKC activity. This phenomenon also provides a widely used tool for studying
PKC-dependence of signal transduction (see Parker, 1992; Rasmussen et al., 1992).
FUNCTION
Similar to various other protein kinases, PKC plays a role in signal amplification from
cell surface through kinase cascades to the nucleus. It also participates in the fine-
tuning of cellular events (Figure 4). In addition to other kinases, PKC phosphorylation
targets include other enzymes, structural proteins, ion channels and receptors
(Aderem and Seyrkora, 1992; Borner and Fabbro, 1992; Jaken, 1992; Knox and
Kaczmarek, 1992). PKC can directly interact with a variety of proteins, not all of them
PKC substrates, an important example being PLD1 (see Ron and Kazanietz, 1999).
PKCi PKCa
DG PA PCPIP2
PLCi
PLCa PLDa
PLDi
IP3
[Ca++]i↑
FIGURE 4. A simplified model of
the interplay of phospholipases C
(PLC) and D (PLD), protein ki-
nase C (PKC), and free intracel-
lular Ca++ ([Ca++]i). PC: phospha-
tidylcholine, PA: phosphatidic
acid, PIP2: phosphatidylinositol
4,5-bisphosphate, DG: diglyce-
ride, IP3: inositol 1,4,5-trisphos-
phate, subscripts i: inactive, a:
active. Closed head arrow indi-
cates an activating effect and
closed circle an inhibitory effect
on adjacent signalling pathways.
PKC-catalysed phosphorylation of nicotinic acetylcholine receptors has been reported
to enhance the receptor recovery from desensitisation in rat chromaffin cells and in
Xenopus oocytes expressing α4β2 receptors, as well as to reduce the deepness of desen-
sitisation of the α4β2 receptors (Khiroug et al., 1998; Fenster et al., 1999). However, in
voltage-clamped chick sympathetic ganglion neurons, PKC activators enhance nicoti-
nic receptor current decay (Downing and Role, 1987). Moreover, an increased number
of human α4β2 receptors in a cell line have been noted in response to a prolonged ex-
posure to PMA but not to PKC inhibitors (Gopalakrishnan et al., 1997), suggesting
PKC-enhanced desensitisation and thus concurring with previous views (Huganir and
Greengard, 1990; Swope et al., 1992). Yet, dephosphorylated nicotinic receptors have
been suggested to be a signal for inhibiting receptor turnover (Peng et al., 1994).
17
BOVINE ADRENAL CHROMAFFIN CELLS
Adrenal medulla originates from the embryonic neural crest and functionally re-
sembles a sympathetic ganglion. In the 1960's, a method for isolating and culturing
gerbil adrenal chromaffin cells was established (Douglas et al., 1967a, 1967b). In the
1970's, bovine chromaffin cell cultures were developed (Schneider et al., 1977), and
within a decade several laboratories adopted and further elaborated these methods
(Kilpatrick et al., 1980; Unsicker and Müller, 1981; Waymire et al., 1983; Wilson,
1987). During this period, chromaffin cells, especially of bovine origin, became a wide-
ly used tool in neurochemical and neurobiological studies (see Livett, 1984).
Bovine adrenal chromaffin cells synthesise noradrenaline and adrenaline. The cells
also have a high-affinity uptake mechanism for catecholamines (Kenigsberg and
Trifaró, 1980). Upon nicotinic stimulation and increased [Ca++]i, the chromaffin cells
quantally secrete not only catecholamines but also peptides, such as enkephalin
(Livett et al., 1981). Bovine adrenal chromaffin cells retain their neural properties in
culture for prolonged periods, whether or not they were allowed to attach to the cul-
ture dish (Kilpatrick et al., 1980; Waymire et al., 1983).
Although the muscarinic receptors of cultured bovine chromaffin cells  are coupled to
phosphoinositide hydrolysis (Eberhard and Holz, 1987; Nakaki et al., 1988), their acti-
vation evokes only weak if any secretion of catecholamines (Ballesta et al., 1989;
Cheek et al., 1989; McKay et al., 1991; Yamagami et al., 1991). Thus, cholinergic ef-
fects on these cells are almost purely nicotinic, in contrast to porcine (Nassar-Gentina
et al., 1997) and feline chromaffin cells (Ballesta et al., 1989).
Similar to sympathetic ganglion cells in general, bovine chromaffin cells express nico-
tinic acetylcholine receptors. In these cells, genes encoding the α3, α5, α7 and β4, but
not the β2, nicotinic acetylcholine receptor subunits are expressed (Criado et al., 1992;
García-Guzmán et al., 1995; Campos-Caro et al., 1997; Wenger et al., 1997). Hence, the
possible subunit combinations are α3β4* with or without an α5 subunit, and α7.
Stimulation of nicotinic acetylcholine receptors on bovine adrenal chromaffin cells
leads to Na+ influx and depolarisation of the plasma membrane. Then [Ca++]i is in-
creased, PLA2 is activated, and transmitters are released (Holz et al., 1982; Frye and
Holz, 1984). Although the secretory events are accompanied by inositol phospholipid
breakdown and PKC activation (TerBush and Holz, 1986; Eberhard and Holz, 1987;
TerBush et al., 1988), and direct PKC activation by phorbol esters can evoke exocyto-
sis, changes in PI-PLC and PKC activity are not necessary for catecholamine secretion
(TerBush and Holz, 1990; Loneragan et al., 1996).
COTININE PHARMACOLOGY
Cotinine structure and synthesis have been known for more than one-hundred years
(Pinner, 1893). Cotinine has mainly been considered a pharmacologically inert meta-
bolite of its psychoactive parent compound (Jaffe, 1990; Anonymous, 1991; Benowitz,
1996; Rang et al., 1999). However, already in the early sixties, the first evidence of
possible cotinine activity was published. The compound was found to be hypotensive
and to abolish the nicotine-induced vasopressor response in dogs (Borzelleca et al.,
1962). Cotinine was also found to have effects opposite to nicotine, first as a rabbit and
rat intestinal smooth muscle relaxant (Kim et al., 1968).
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Cotinine was then reported to counteract the catecholamine decreases secondary to ty-
rosine hydroxylase inhibition in the rat (Eneroth et al., 1977). The same group further
reported a nicotine-like reduction in 5-hydroxytryptamine turnover by cotinine in the
rat brain. The effects of nicotine on the central nervous system were speculated to be
in part mediated by cotinine, independently of nicotinic acetylcholine receptors (Fuxe
et al., 1979). In mice, cotinine has been reported to mimic nicotine as an antinoci-
ceptive compound (Erenmemisoglu and Tekol, 1994) and in counteracting ethanol-in-
duced incoordination (Dar et al., 1994). Recently, a cotinine-evoked dopamine release
from rat striatal slices has been reported (Dwoskin et al., 1999). In humans, cotinine
slightly worsens nicotine withdrawal symptoms (Keenan et al., 1994), and it elimi-
nates the beneficial effects of a nicotine patch (Hatsukami et al., 1998).
Outside the nervous system, cotinine has been reported to affect eicosanoid release
both in a nicotine-like manner (Saareks et al., 1993) and differently from nicotine
(Chahine et al., 1990). Moreover, in steroid metabolism both nicotine-like (Patterson et
al., 1990) and nicotine-unlike effects (Andersson et al., 1993) have been detected.
Although cotinine has been nearly or totally inert in receptor binding assays (Abood et
al., 1983, 1985), it seemingly has pharmacological activity. The question arises as to
whether biological activity of cotinine is mediated through nicotinic acetylcholine re-
ceptors; by activation, desensitisation or blockade.
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AIMS OF THE STUDY
As outlined in the previous section, cotinine pharmacologically acts on neural systems,
but its effects remain obscure. Since cotinine is structurally related to nicotine, its
probable targets include nicotinic receptors, through which it can modify nicotinic
responses. PLD, in turn, is a good candidate for catalysing the nicotine-evoked
prolonged diglyceride production and sustaining the increased PKC activity. The
finding – presented in a single report at the time this work was planned – that PLD is
lacking from bovine chromaffin cells does not concur with this hypothesis. If PLD acti-
vity exists in chromaffin cells, it may well have a role in nicotinic signalling.
The aim of the present study was to clarify whether:
1 receptor-linked PLD activity exists in bovine adrenal chromaffin cells;
2 PLD participates in nicotine signalling, especially in sustained kinase activation;
3 cotinine modulates the effects of nicotine on intracellular (PKC activity, [Ca++]i) and
intercellular (noradrenaline release) chromaffin cell signalling;
4 cotinine itself evokes chromaffin cell responses; and
5 cotinine effects are mediated by nicotinic acetylcholine receptors.
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MATERIALS AND METHODS
CELL CULTURE
Bovine adrenal glands were obtained from local slaughterhouses. They were carried to
the laboratory chilled in an ice bath. The medullae were digested by retrograde
perfusion through the central vein with collagenase B (Roche Molecular Biochemicals /
Boehringer Mannheim Biochemicals, Mannheim, Germany), and the medullary
suspension was purified by centrifugation through a meglumine diatrizoate – sodium
diatrizoate gradient (made in the laboratory, or available commercially as Urografin®
from Schering AG, Berlin, Germany). Purification was continued by differential
plating in tissue culture flasks for two to three hours. The cells were plated on
appropriate dishes or plates (Wilson and Viveros, 1981; Waymire et al., 1983; Wilson,
1987; Tuominen et al., 1991), grown in standard medium (Dulbecco's modified Eagle's
medium/Ham's nutrient mixture F12 with 10% foetal calf serum and antibiotics), and
used within a week of preparing the culture. The cultures yielded 10 – 120 x 106 cells
per gland. Despite differences in cell yield, cultures were consistently of ≥ 90% purity
as estimated by neutral red staining.
PLD SAMPLE PREPARATION AND ASSAY
The cells were labelled with [3H]oleic acid or [3H]myristic acid (both from Amersham,
Buckinghamshire, UK) for 24 h. They were then washed with isotonic saline and gent-
ly suspended in an appropriate buffer (pH 7.4 at 37°C): based on bicarbonate (5% CO2
atmosphere) or on N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES,
room air). The assay was based on a PLD-catalysed characteristic reaction, where
primary alcohol replaces water in accepting the phosphatidyl moiety. The
phosphatidylalcohol thus formed is more stable than phosphatidic acid and can be
used as a measure of PLD activity (see Morris et al., 1997a). Hence, the cells were
exposed to stimulants in the presence of 50 mM n-butanol (I) or 220 mM ethanol (II).
In 1-h exposures, the alcohol was present for the last 15 min.
The lipids were extracted with chloroform : methanol : water (10 : 10 : 9, by volume),
acidified with HCl (Bligh and Dyer, 1959). The chloroform phase was collected, the sol-
vent was evaporated, and the lipid residue was redissolved in chloroform : methanol (9
: 1). The phospholipids were then separated by thin layer chromatography (LK6D
plates from Whatman, Clifton, NJ, USA). The solvent used for phosphatidylbutanol
separation was the upper phase of ethylacetate : isooctane : acetic acid : water (13 : 2 :
3 : 10) (Liscovitch and Amsterdam, 1989). When phosphatidylethanol was formed,
oxalate-coated thin layer chromatography plates were used with a chloroform :
methanol : acetic acid : water (75 : 45 : 3 : 1) mixture as the solvent (Horwitz, 1991;
Caumont et al., 1998). Phosphatidylalcohol markers were run along with the samples.
The phospholipids on chromatography plates were stained with iodine.
Phosphatidylethanol and phosphatidylbutanol standards were prepared from 1-
palmitoyl-2-oleyl phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL, USA) by
Streptomyces sp. PLD (Sigma, St. Louis, MO, USA), as previously described (Eibl and
Kovatchev, 1981; Kobayashi and Kanfer, 1987; Comfurius et al., 1990). A two-phase
system consisting of 50 ml l-1 n-butanol or ethanol, 450 ml l-1 chloroform, and 500 ml l-1
185 mM Tris buffer (pH 7.4) with 185 mM CaCl2, was used. The mixture was shaken
for 2 – 4 h at 37°C. The lipids were extracted as above (Bligh and Dyer, 1959).
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WESTERN BLOT
The cultured cells were washed and homogenised by sonication in the presence of
protease inhibitors phenylmethylsulfonyl fluoride 1 mM and leupeptin 250 µg ml-1.
The protein extracts were prepared by high-acceleration centrifugation (100 000 x g,
45 – 60 min), first in the absence and then in the presence of 0.1% Triton X-100 to
extract the soluble and membrane proteins, respectively. The extracts were
denatured, and the protein samples were separated in 8% polyacrylamide gels
(Laemmli, 1970) and transferred to nitrocellulose membranes (Schleicher & Shüll,
Dassel, Germany) by semi-dry electroblotting (SemiPhor™, Hoefer Pharmacia
Biotech, San Fransisco, CA, USA). The membranes were blocked in 5% fat-free milk,
exposed to antibodies, and the immunoreactive proteins were detected by enhanced
chemiluminescence reaction (Durrant, 1990; Crisp and Dunn, 1994).
Rabbit anti-rat PKC antisera were a generous gift from Dr. William C. Wetsel
(NIEHS, NC, USA). They were raised against carboxyterminal peptides of PKC isoen-
zymes as follows: SYVNPQFVHPILQSAV (α), SYTNPEFVINV (β1), SFVNSEFLKPE-
VKS (β2), DARSPTSPVPVPVM (γ), SFVNPKYEQFLE (δ), KGFSYFGEDLMP (ε),
EYINPLLLSAEESV (ζ), and their preparation and properties have previously been
described (Wetsel et al., 1992). Anti-PLD antibody, against sequence CIIGSANINERS,
was a product of Upstate Biotechnology, Lake Placid, NY, USA. Goat anti-rabbit
secondary antibody was purchased from Bio-Rad Laboratories, CA, USA.
PROTEIN ASSAY
The protein concentrations of the extracts were determined according to Bradford
(1976). The dye reagent was either commercial (III, IV; Bio-Rad, Richmond, CA, USA),
or it was prepared from Serva Blue G (I, VI; Serva, Heidelberg, Germany). The protein
standards were prepared from bovine serum albumin concentrate (Pierce, Rockford,
IL, USA).
[3H]NORADRENALINE RELEASE
The experiments were run largely as previously described (McKay and Schneider,
1984), in saline buffered with HEPES and NaHCO3 (pH 7.4 at 5% CO2). Ascorbic acid
1 mg ml-1 was added to the medium to avoid oxidation of the catecholamines. To get a
lower non-specific release, 1 mg ml-1 bovine serum albumin was added in some experi-
ments (II, IV). The cell catecholamine pools were labelled with 500 nM [3H]nor-
adrenaline (Amersham, 22 kBq ml-1) for 10 min (II, IV) or 60 min (III). Then, the cells
were washed and exposed to stimulants as indicated. The treatments were terminated
by pipetting the medium into scintillation vials or plates. The cells were disrupted in
0.1% Triton X-100 before transferring them to scintillation vials or plates. Results are
expressed as percentages of total cellular [3H]noradrenaline contents released.
MEASUREMENT OF [Ca++]i
The cells were washed and gently resuspended in experiment buffer (NaCl 118 mM,
KCl 5 mM, MgSO4 1 mM, CaCl2 1 mM, HEPES 20 mM, glucose 10 mM, pH 7.4). The
cells were labelled with 5 µM Fura 2-AM (Molecular Probes, Eugene, OR, USA) for the
first 10 min, and then with 500 nM Fura 2-AM for an additional hour (McMillian et
al., 1992). Then, the cells were washed, incubated for at least 10 min and washed
again. All the incubations were performed in the dark to avoid photobleaching. For ex-
22
periments in a Ca++-free environment, CaCl2 was omitted from the experiment buffer
and 100 µM ethylene glycol-bis(β-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA)
was added. Measurements were performed at room temperature in a quartz cuvette (2
x 106 cells/ml), with a Hitachi F2000 fluorometer essentially as previously described
(Törnquist et al., 1999). The excitation wavelengths were 340 nm and 380 nm, and the
emission wavelength was 510 nm. [Ca++]i was calculated as previously described
(Grynkiewicz et al., 1985), using a software designed for the fluorometer. The Kd value
for Fura 2 was 224 nM.
CYTOTOXICITY TEST
The cells were exposed to the test compounds for the desired time. In the 24-hour ex-
periments, 0.5 mg ml-1 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT; Sigma, St. Louis, MO, USA) was added three hours before stopping the treat-
ment. In short experiments, MTT was present throughout the incubation. For measur-
ing toxicity, media were aspirated and replaced with dimethyl sulfoxide. After shaking
for 5 min, the absorbances were read at 540 nm to estimate the MTT reduction. The
extent of reduction was considered as a measure of mitochondrial function and cell
survival (Supino, 1990).
PKC ASSAY
Standard methods (Kikkawa et al., 1983; Roskoski, 1983), with some modifications
(Tuominen et al., 1991), were used. Treatments were stopped by washing the cells
with ice-cold Ca++-free medium (pH 7.5). Cells were disrupted by sonication. The sus-
pension was centrifuged (100 000 x g, 60 min, 4°C), first without (soluble extract) and
then with (particulate extract) 1 ml l-1 Triton X-100. In the assay, the protein extracts
were allowed to catalyse histone (0.3 mg ml-1 calf thymus histone type III-S; Sigma)
phosphorylation for 5 min at 30°C in the presence of adenosine γ-32P-triphosphate
(Amersham), both with and without the PKC activators: 1 mM CaCl2, 40 µg ml-1 phos-
phatidylserine and 8 µg ml-1 1,2-sn-dioctanoylglycerol. The reaction was terminated by
spotting reaction mixture onto P81 phosphocellulose paper (Whatman, Maidstone,
UK), and washing the papers in 75 mM phosphoric acid. The trapped radioactivity
was counted after air-drying. PKC activity was calculated by subtracting the non-spe-
cific activity from total activity. Results are expressed as nmoles of inorganic phos-
phate incorporated into histone min-1 mg-1 of protein.
[3H]PHORBOL-12,13-DIBUTYRATE BINDING
For short treatments, the growing medium was replaced by HEPES- and NaHCO3-
buffered saline (pH 7.4 at 5% CO2), and the cells were allowed to stabilise for 60 min.
[3H]Phorbol-12,13-dibutyrate (PDBu, Amersham) with (non-specific binding) or with-
out (total binding) 1 µM phorbol 12-myristate 13-acetate (PMA) was added into the
wells. The 24-h experiments were run in the growing medium, and 15 min before stop-
ping the treatment [3H]PDBu with or without PMA was added. The final concent-
ration of [3H]PDBu was 10 nM. Treatments were terminated by washing the cells with
isotonic saline. The bound radioactivity was measured, and results are expressed as
specific binding.
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ANIMALS
Adult female Wistar rats (HsdBrlHan:WIST) with free access to food and water were
used. Brains were obtained after decapitation, and brain areas were dissected on ice.
The study protocol was approved by the University of Helsinki ethics committee for
animal experiments.
RECEPTOR BINDING
Tissues and cells were homogenised in a glass-teflon homogeniser in hypotonic Tris
buffer containing protease inhibitors. The homogenates were spun twice at 30 000 x g
for 15 min, and the pellets were resuspended in fresh buffer. [3H]Epibatidine (NEN
Life Science Products, Boston, MA, USA) was used as the nicotinic label. The experi-
ments were performed in polypropene tubes in 50 mM Tris HCl buffer (pH 7.4) at
37°C. The binding time was 4 h. To determine non-specific binding, 300 µM nicotine
was added to the incubations. In saturation binding experiments, the [3H]epibatidine
concentration was 14.5 pM – 6.75 nM (chromaffin cells) or 10 pM – 2.15 nM (brain). In
competition experiments, single concentrations of 100 pM (chromaffin cells) and 250
pM (brain) were used. The incubations were terminated by using Brandell M-24R cell
harvester. The bound ligand was trapped in Whatman GF/B filters presoaked for five
hours in 5 mg ml-1 polyethyleneimine, and the filters were washed three times with
cold Tris buffer. The filters were counted for radioactivity after overnight incubation
in the scintillation liquid.
CHEMICALS
If not otherwise stated, the chemicals were obtained from standard commercial
sources. Inorganic salts and solvents were of analysis grade and were supplied by
Merck, Darmstadt, Germany and by J.T. Baker, Deventer, The Netherlands. The
pharmacological agents and the cell culture media were mostly from Sigma, St. Louis,
MO, USA. Other suppliers included Tocris Cookson, Bristol, UK; Alomone Labs,
Jerusalem, Israel; and LC Services, Woburn, MA, USA.
DATA ANALYSIS
Arithmetic means, standard deviations and standard errors of means were calculated
from the numeric data. Parametric tests were preferred whenever data distribution
allowed. Angular transformation for percentage data was done if required to
homogenise the variances (IV). In comparing two groups with a dependent variable,
paired t-test was used (V).
Primarily, analysis of variance was used for estimating the existence of differences.
Repeated measures tests were used where appropriate (II, V). Post hoc tests for mul-
tiple comparisons were Tukey's test (II – IV) or Dunnett's test (II, V). For non-para-
metric analyses, the Kruskall-Wallis test was used to evaluate whether a difference
existed between any groups. Non-parametric post hoc tests were done using Mann-
Whitney U-test, followed by Dunn-Sidak (I) or Bonferroni (III) procedure.
For receptor binding data (VI), nonlinear regression analyses were used. The data
were fitted to one-site and two-site models, and the fits were compared by F-test. The
analyses were performed with Prism 2.0b for Macintosh (GraphPad Software, San
Diego, CA, USA).
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RESULTS
PLD IN CHROMAFFIN CELL SIGNALLING
The anti-PLD antibody detected a protein of apparent molecular weight of 105 kDa in
the particulate protein fraction of adrenal medullary chromaffin cell homogenates. In
the soluble fraction, the antibody detected several proteins, all giving only a weak
signal (I).
Upon stimulation by angiotensin II (200 nM), bradykinin (100 nM), or PMA (1 µM) in
the presence of 50 mM n-butanol, a significant accumulation of phosphatidylbutanol
was detected in 5- and 15-min treatments. When butanol was present for the last 15
min of 1-h drug exposure, only PMA was able to sustain a significant transphosphati-
dylation activity (I).
To assess whether nicotine increases transphosphatidylation activity, ethanol was
used instead of n-butanol. Neither 10 µM nicotine nor cell depolarisation by 56 mM K+
had any effect in 10-min exposures. However, 1 µM PMA greatly increased the
accumulation of phosphatidylethanol (II). The stimulant effects on phosphatidyl-
ethanol accumulation remained unaffected by replacing [3H]oleate with [3H]myristate
in phospholipid labelling.
If PLD and phosphatidic acid are crucial in catecholamine exocytosis, primary alcohols
should efficiently inhibit secretion. However, ethanol only weakly inhibited nicotine-
and KCl-evoked exocytosis, and no selectivity of the primary alcohols over sec- and
tert-butanol, regarded as poor PLD substrates, in inhibition of catecholamine
exocytosis was detected. Interestingly, n-butanol somewhat increased noradrenaline
exocytosis in the absence of other stimulants (II).
Since the inhibitory effect of alcohols on catecholamine release appeared not to be sec-
ondary to trapping phosphatidic acid, I recorded their effect on chromaffin cell [Ca++]i.
All the alcohols raised [Ca++]i, even in the absence of extracellular Ca
++. They also inhi-
bited a secretagogue-evoked further increase in [Ca++]i (Table 4; II). An increased
fluorescence upon excitation with 340 nm light was always accompanied with a de-
creased fluorescence upon excitation with 380 nm light.
TABLE 4. Effect of 260 mM ethanol and 160 mM butyl alcohols on [Ca++]i in chromaffin cells in buffer
containing either 1 mM CaCl2 or no Ca
++ but 100 µM EGTA, and on the increase in [Ca++]i evoked by
sequentially added 10 µM nicotine and 56 mM KCl, or addition of 1 mM CaCl2.
1 mM     CaCl  2 Ca 
++ -free  
Alcohol Nicotine KCl Alcohol 1 mM CaCl   2
control -1.2 ± 1.0 380 ± 40 530 ± 42 -1.3 ± 0.60 120 ± 13
ethanol 63 ± 11* 290 ± 29* 420 ± 33** 23 ± 2.9 140 ± 16
n-butanol 380 ± 26** -2.3 ± 1.3** 7.6 ± 5.6** 130 ± 14** 270 ± 32**
sec-butanol 230 ± 18** 12 ± 11** 100 ± 5.8** 120 ± 7.5** 180 ± 11*
tert-butanol 200 ± 18** -3.3 ± 1.6** 210 ± 17** 52 ± 3.3** 180 ± 17*
Values reflect the change in [Ca++]i in nM (mean ± standard error). Asterisks indicate statistically
significant differences vs. corresponding controls by Dunnett's test (*p < 0.05, **p < 0.01).
The alcohol-evoked apparent increase in [Ca++]i could be due to cytotoxicity. However,
a 2-h exposure to the alcohols at the concentrations used in the noradrenaline release
and [Ca++]i experiments was not cytotoxic to chromaffin cells, as estimated by reduc-
tion of MTT (II).
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COTININE EFFECTS ON CHROMAFFIN CELLS
In agreement with previous knowledge (Tuominen et al., 1992), nicotine was observed
to increase specific [3H]phorbol dibutyrate binding, reflecting PKC activity, to
chromaffin cells upon both 15-min and 24-h exposures. Cotinine alone also increased
[3H]phorbol dibutyrate binding upon 15-min but not 24-h exposure. Nonetheless,
cotinine pretreatment for 10 min, at 1 mM and higher concentrations, and for 24 h, at
100 µM – 10 mM, resulted in a decrease in the nicotine-induced binding (III).
The altered [3H]phorbol dibutyrate binding suggested redistribution of PKC. In
enzyme assays, a 24-h incubation of the cells with 1 mM cotinine failed to increase the
PKC kinetic activity in the particulate protein fraction. However, the nicotine-induced
increase in membrane-bound PKC activity was markedly decreased by the same
treatment (III). Cytotoxicity of cotinine could in part explain its inhibitory effect on
nicotine-induced PKC activity. Nevertheless, significant inhibition in the MTT
reduction was detected only at higher concentrations than those used in the PKC and
phorbol-binding assays (III).
When the chromaffin cells were incubated in the absence of stimulants after a 60-min
labelling period with [3H]noradrenaline, the basal [3H]noradrenaline release over a 20-
min period was 7 – 8% of the cellular contents (III). Nicotine and DMPP, for the latter
10 min, dose-dependently increased the release as anticipated. A 10-min pre-
incubation with 10 mM cotinine increased basal release slightly but significantly (III).
To reduce non-specific noradrenaline release, 2 mg ml-1 bovine serum albumin was
added to the incubation buffer. In addition, the labelling time with [3H]noradrenaline
was reduced to 10 min. These measures drastically reduced basal label release during
incubations of 10 s – 20 min. Under these circumstances, cotinine concentration- and
time-dependently stimulated [3H]noradrenaline exocytosis (Table 5; IV).
TABLE 5. Time-dependence of cotinine-evoked [3H]noradrenaline release as percentage of cellular label.
10 s 60 s 10 min 20 min
control 0.35 ± 0.055 1.1 ± 0.092 1.4 ± 0.080 1.9 ± 0.32
peak effect (at [cotinine]) 1.4 ± 0.13 (32 mM) 5.9 ± 0.17 (10 mM) 28 ± 0.27 (3.2 mM) 31 ± 0.98 (3.2 mM)
effect of 10 µM nicotine 0.58 ± 0.070 5.0 ± 0.21 33 ± 0.21 37 ± 0.87
Cotinine clearly and significantly inhibited the release caused by nicotine and DMPP.
The effect of cotinine on nicotine-evoked release was dose-dependent. However, coti-
nine did not appear to be a general membrane-stabilising agent, as the exocytotic ef-
fects of high extracellular K+ (56 mM) and veratrine (10 mg l-1) were not reduced. In-
deed, cotinine slightly but significantly increased the veratrine-induced release (III).
Cotinine, at concentrations of 10 – 32 mM, also significantly increased the binding of
[3H]phorbol dibutyrate to chromaffin cells in 15-min but not in 24-h incubations. This
effect was inhibited by the nicotinic receptor channel blocker hexamethonium. In line
with this, a 30-min exposure to 10 mM cotinine increased the membrane-associated
PKC activity (IV). The PKC isoenzymes activated by cotinine appeared to be cPKCα
and nPKCε, as indicated by Western blot. The cPKCβ1 and cPKCβ2 were not
translocated, while the anti-rat PKC antibodies against γ, δ and ζ isoenzymes recog-
nised no protein in the bovine chromaffin cell electrophoresis preparations (IV).
The cotinine-evoked effects on noradrenaline release could well be mediated by nicoti-
nic acetylcholine receptor activation and increased [Ca++]i. Indeed, cotinine, at concen-
trations of 320 µM and higher, increased the [Ca++]i. The effect of cotinine on [Ca++]i
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was inhibited by both competitive and non-competitive nicotinic receptor antagonists,
as well as by omitting extracellular Ca++ (V). Inhibition occurred, in part, by blocking
the voltage-dependent L-type calcium channels by 300 nM nimodipine. Emptying the
endoplasmic reticular Ca++ stores with 1 µM thapsigargin, a Ca++-ATPase inhibitor,
increased the chromaffin cell [Ca++]i but had no effect on the response to cotinine. Nor
did the blockade of voltage-sensitive sodium channels with 10 µM tetrodotoxin affect
the cotinine-induced increase in [Ca++]i (V).
In addition to its own effect, cotinine dose-dependently inhibited the nicotine-induced
rise in [Ca++]i. Reciprocally, nicotine pretreatment inhibited the cotinine-induced rise
in [Ca++]i. Cotinine also inhibited the effect of administration of additional cotinine (V).
COTININE BINDING TO NICOTINIC ACETYLCHOLINE RECEPTORS
Finally, a nicotinic receptor binding assay for bovine chromaffin cell membrane homo-
genates was established. The radioligand, [3H]epibatidine, bound to membranes in a
saturable fashion. Upon analysis, the Rosenthal plots appeared curvilinear, and a
non-linear regression analysis revealed a significantly better fit for two-site than for
one-site binding. The apparent Kd values were 93 pM and 1 400 pM, with Bmax values
of 98 fmol mg-1 and 220 fmol mg-1, respectively (VI).
Cotinine, as well as the competitive nicotinic receptor ligands nicotine,  methyllycaco-
nitine and dihydro-β-erythroidine displaced 100 pM and 1 nM [3H]epibatidine from its
chromaffin cell binding sites, fitting to a one-site binding model (VI). Nicotine was the
most potent of the competitors tested (concentrations causing half-maximal inhibition
0.30 and 1.6 µM upon labelling with 100 pM and 1 nM [3H]epibatidine, respectively),
followed by methyllycaconitine (1.9 and 4.8 µM), dihydro-β-erythroidine (75 and 160
µM) and cotinine (130 and 310 µM). Alpha-bungarotoxin, over a concentration range of
100 pM – 10 µM, was unable to displace 100 pM [3H]epibatidine. However, 10 nM – 10
µM α-bungarotoxin displaced 17 % of the bound radioligand upon labelling with 1 nM
[3H]epibatidine.
In rat frontal cortex and hippocampus, the [3H]epibatidine saturation binding was
consistent with a one-site model. The affinity was twice that observed for chromaffin
cell high-affinity sites. In frontal cortex and hippocampus, nicotine affinity (Ki 8.6 – 13
nM and 12 – 22 nM, respectively) was ten times and cotinine affinity (Ki 2.3 – 3.8 µM
and 3.0 – 4.8 µM) even more higher than in the chromaffin cell preparation (VI).
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DISCUSSION
METHODOLOGICAL CONSIDERATIONS
To evaluate whether functional PLD activity in bovine chromaffin cells exists, the cells
were exposed to primary alcohol together with the stimulants. In such a medium, PLD
yields metabolically more stable phosphatidylbutanol instead of phosphatidic acid
(Thompson et al., 1991; Singer et al., 1997). The phosphatidylalcohol was allowed to
accumulate for 5 – 15 min, which was considered sufficiently long to answer the ques-
tion of whether PLD activity in chromaffin cells could be stimulated in a receptor-me-
diated manner or by PMA, a universal activator of PLD1. In the first studies, n-buta-
nol was used as the substrate alcohol. Since at the 50 mM concentration used in PLD
assay, n-butanol inhibits nicotinic responses (Harper and Littleton, 1990) and voltage-
activated channels (Elliott and Elliott, 1994), ethanol was used when nicotinic re-
sponses were studied.
In noradrenaline secretion experiments, the addition of albumin to the release buffer
greatly reduced the basal release, as also previously recorded (Powis and O'Brien,
1991). Furthermore, adequate dose-response curves for cotinine were obtained only in
the presence of albumin, while in its absence spontaneous release or overflow may
have masked much of the effect, especially at lower concentration.
In histone kinase assay, some of the PKC activity remains undetected because histone
is phosphorylated only by the conventional PKC isoenzymes, α, β and γ, requiring both
diglycerides and Ca++ for their activation (Marais and Parker, 1989; Schaap et al.,
1989; Olivier and Parker, 1991; Liyanage et al., 1992). Moreover, since a risk of PKC
redistribution and proteolysis exists during sample preparation, methods, such as
phorbol binding, avoiding major sample preparation steps are indicated.
[3H]Phorbol-12,13-dibutyrate binding can be performed utilising intact cells. There-
fore, sample preparation, with the associated risks therein, is not needed. In short-
term incubations with substimulatory concentrations of the phorbol ester, the binding
occurs at membrane-translocated PKC and reflects the in situ PKC activity (Trilivas
and Brown, 1989; Rasmussen et al., 1992). In primary cultures of bovine adrenal me-
dullary cells, prepared essentially as in the present work, the non-chromaffin cells re-
present only 7% of the total specific binding (Tuominen et al., 1991). Thus, phorbol
binding can be reasoned to be a valid measure of PKC activity in the chromaffin cell
model. However, other receptors for phorbol esters also exist (Ron and Kazanietz,
1999).
Although kinase assay using different subcellular extracts is a widely used method for
demonstrating PKC translocation, Western blot has been claimed to be the only reli-
able way to demonstrate PKC translocation (Parker, 1992), and it is the only way of
showing the isoenzyme-specific changes. Nevertheless, it is complicated by species-
specific differences in protein sequences and immunogenic properties. Bovine-specific
antibodies against PKC isoenzymes are not readily available, and the only sequenced
bovine isoenzymes are conventional (Bairoch and Apweiler, 1999). In the present
work, most of the PKC antibodies raised against rat carboxyterminal sequences
(Wetsel et al., 1992) cross-reacted with bovine proteins. However, the anti-
EYINPLLLSAEESV antibody failed to recognise the bovine aPKCζ, although the iso-
enzyme has previously been detected in bovine chromaffin cells with an apparent mo-
lecular weight of 80 000 (Pavlovic-Surjancev et al., 1993).
28
PHOSPHOLIPASE D IN CHROMAFFIN CELL NICOTINIC RESPONSES
PLD activity has previously been suggested to be lacking from bovine adrenal chro-
maffin cells, as no accumulation of [32P]phosphatidylbutanol was observed in [32P]i pre-
labelled cells treated with 50 mM butanol and either PMA or bradykinin (Purkiss et
al., 1991). Contradictory results have also been obtained (García et al., 1992; Caumont
et al., 1998), but the existence of PLD in bovine chromaffin cells had yet to be con-
firmed (Boarder, 1993; García et al., 1993; Glenn et al., 1998). Interestingly, the nico-
tine-evoked activation of PLD (Caumont et al., 1998) has not been invariably recorded,
and nicotine has actually been reported to inhibit PLD activation induced by β amy-
loid in a neuroblastoma cell line (Singh et al., 1998).
The present study demonstrates the existence of a 105 kDa protein detected by anti-
PLD antibody in bovine adrenal chromaffin cells. As sequences similar to the peptide
CIIGSANINERS, against which the antibody was raised, are known only in the PLD
proteins (Bairoch and Apweiler, 1999), the finding strongly suggests the existence of
PLD in the chromaffin cells. Immunoreactivity was detected mainly in the particulate
protein fraction. This is in agreement with previous findings that PLD is mainly asso-
ciated with various membrane structures. However, the subcellular localisation of
PLD may vary between cell types (Provost et al., 1996; Brown et al., 1998).
The present results clearly demonstrate that activation of PKC by PMA and receptor-
mediated stimulation by Sar1-angiotensin II and bradykinin increase transphosphati-
dylation activity in bovine adrenal chromaffin cells, in contrast to results previously
obtained with bradykinin and PMA stimulations of [32P]i prelabelled cells (Purkiss et
al., 1991). Differences in labelling are unlikely, at least alone, to explain the different
results. A possible explanation is the difference in the number of cells per sample,
which was 15 times higher in the present study. An increased PLD activity was sus-
tained for an hour upon continuous exposure to PMA. However, I was unable to dem-
onstrate a prolonged activation of PLD by Sar1-angiotensin II or bradykinin. In this
sense, the role of PLD in chromaffin cells differs from that in adrenal cortical cells,
which sustain PLD activity upon a continuous exposure to angiotensin II (Jung et al.,
1998). When phosphatidylethanol formation was measured, nicotine and a depolaris-
ing concentration of potassium had no effect on PLD activity, while PMA again
strongly stimulated the enzyme. This lies in stark contrast to a previous report despite
largely similar methodology (Caumont et al., 1998). The signalling pathway leading to
angiotensin- and nicotine-induced prolonged diacylglycerol production and protein
kinase C activity in bovine chromaffin cells thus remains to be clarified. The putative
PC-PLC may still have a crucial role as previously suggested (Liscovitch, 1992;
Nishizuka, 1992).
PLD activation has been hypothesised to play an important role in exocytosis from va-
rious cell types, including PC12 phaeochromocytoma cells (Kanoh et al., 1992;
Cockcroft, 1996). If PLD is crucial for chromaffin cell exocytosis, trapping phosphatidic
acid by primary alcohols should inhibit secretion. In my study, this inhibition did oc-
cur. However, no selectivity of primary alkanols over sec- and tert-butanol was de-
tected. This is in line with previous findings on alkanol effects (Harper and Littleton,
1990; Wood et al., 1991; Alifimoff et al., 1993), but largely conflicts with the results
and interpretation of Caumont et al. (1998).
All the butyl alcohols tested efficiently inhibited induction of further Ca++ transients
by secretagogues. Ethanol, at the same mass concentration, was less efficient. The
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reason for reduced exocytosis by nicotine and K+ from bovine chromaffin cells thus
appears to lie on the cell membrane. The effects of the alkanols on exocytosis, at
concentrations adopted from Caumont et al. (1998), seemingly are not PLD-dependent.
The role of PLD in chromaffin cell exocytosis is further questioned in that highly
active bacterial PLD does not reconstitute the Ca++-dependent exocytosis from
permeabilised bovine chromaffin cells (Glenn et al., 1998). The different results
between the present and the previous studies (Purkiss et al., 1991; Caumont et al.,
1998) cannot be fully explained, although differences in the cell preparation and
culture conditions cannot be ruled out as a source of variation.
Interestingly, all the alcohols tested raised the [Ca++]i. The effect was reduced but not
totally abolished in the absence of extracellular Ca++, suggesting a release from the in-
tracellular stores. Although n-butanol increased the [Ca++]i roughly as much as nico-
tine, it only weakly stimulated the noradrenaline secretion. A similar phenomenon is
known to occur upon exposure to thapsigargin (Xu et al., 1992), suggesting the possibi-
lity that the [Ca++]i response is initiated at the level of endoplasmic reticular Ca
++
stores, and the secretion remains small despite increased [Ca++]i. However, the
possible store-emptying effect of alcohols does not explain the reduced response to
nicotine (Mollard et al., 1995).
COTININE PHARMACOLOGY
In the present study, cotinine inhibition of nicotinic responses was detected in several
parameters: phorbol-12,13-dibutyrate binding, PKC activity, noradrenaline release
and [Ca++]i. As no inhibition of responses evoked by cell depolarisation by veratrine or
high K+ were detected, involvement of nicotinic receptors in the responses seems
probable. In addition, cotinine as such evoked responses mimicking those of nicotine:
it evoked noradrenaline release, stimulated phorbol-12,13-dibutyrate binding,
increased membrane-associated PKC activity and raised [Ca++]i, many of these being
reversed by nicotinic antagonists. Furthermore, cotinine inhibited its own effects on
[Ca++]i, and its effects were also inhibited by nicotine. The maximum effect of cotinine
on noradrenaline release was followed by a reduction in the response, as happens also
upon exposure to nicotine (Kilpatrick et al., 1980; Livett et al., 1981). In prolonged
incubations, the peak cotinine effect on noradrenaline release was smaller than that
observed with 10 µM nicotine. These results altogether suggest that cotinine is a low-
affinity partial nicotinic agonist at chromaffin cell acetylcholine receptors, also capable
of desensitising the receptors.
My results on the effects of ion channel blockers on cotinine-evoked Ca++ transients
are in accord with findings that micromolar tetrodotoxin has only a minor, if any, ef-
fect on exocytosis from chromaffin cells stimulated with 10 – 100 µM acetylcholine
(Kilpatrick et al., 1981), and that at submicromolar concentrations, nimodipine re-
duces 45Ca++ uptake evoked by nicotinic stimulation into chromaffin cells only in part
(Gandia et al., 1991). At micromolar concentrations, nimodipine and various other L-
type calcium channel antagonists inhibit nicotinic receptor ion fluxes (Donnelly-
Roberts et al., 1995), hence raising nimodipine concentrations from the 300 nM used
would have been inadequate. Therefore, I reason that the cotinine-evoked Ca++ influx
largely occurs through nicotinic cholinergic receptors. The submicromolar increases in
[Ca++]i detected might well be mediated by chromaffin cell nicotinic receptor channels,
as previously calculated (Zhou and Neher, 1993).
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The binding of cotinine to chromaffin cell nicotinic acetylcholine receptors at concen-
trations roughly comparable with those needed to evoke responses was also es-
tablished in the present study. Thus, the questions raised originally and along this
work have largely been answered. Nevertheless, the affinity of cotinine to nicotinic
acetylcholine receptors in the bovine chromaffin cells was weak, and the low micro-
molar concentrations reached upon human nicotine administration (Benowitz et al.,
1983; Benowitz and Jacob, 1994) are unlikely to stimulate the receptors. The same
appears true for frontal cortical and hippocampal nicotinic receptors, although they
more avidly bind cotinine. Indeed, the affinity data are in agreement with the ob-
served functional potency difference of cotinine between chromaffin and central neu-
ronal preparations (Dwoskin et al., 1999).
In the present model, cotinine effects are seemingly evoked by activation of the nico-
tinic acetylcholine receptors. This leads to Ca++ influx through the receptors and volt-
age-operated calcium channels, activation of PKC and noradrenaline release. The
PKC isoenzymes activated include cPKCα and nPKCε in chromaffin cells. The PKC
activation is probably mediated by Ca++-stimulated PI-PLC, since the nPKCε per se is
Ca++-independent. Yet, cotinine increased [Ca++]i similarly in both thapsigargin-
treated and control cells. This suggests that in cotinine-induced chromaffin cell activa-
tion, the release of Ca++ from endoplasmic reticulum plays only a minor, if any, role.
Despite being considered important in the exocytotic process of various cell types
(Kanoh et al., 1992; Cockcroft, 1996), PLD does not appear to be involved in the nico-
tinic or depolarisation-evoked signalling in bovine chromaffin cells, although the con-
verse has also been reported (Caumont et al., 1998).
Bovine chromaffin cells express genes encoding the α3, α5, α7 and β4, but not the β2,
nicotinic acetylcholine receptor subunits (Campos-Caro et al., 1997; Wenger et al.,
1997). Thus, α3β4* heteromers, containing or lacking the α5 subunit, and α7 homo-
mers are the possible pentameric subunit combinations. The human α7 homomers are
only weakly activated but readily inhibited by cotinine (Briggs and McKenna, 1998),
and their activation by nicotine requires high micromolar concentrations (Briggs et al.,
1999). When my findings on cotinine effects on noradrenaline release and Ca++ tran-
sients are reflected against the existing data on mammalian α7 receptors, these do not
appear the probable target of cotinine in bovine adrenal chromaffin cells.
My results demonstrating two agonist affinity classes of receptors on bovine adrenal
chromaffin cells are different from a report based on [3H]nicotine as the label (Lee et
al., 1992). The different affinities may reflect different receptor compositions or they
may indicate the presence of receptors with different affinity states. The 15-fold diffe-
rence between the high- and low-affinity sites observed in the present work agrees
with the 15- to 50-fold difference observed in α3* receptors of human neuroblastoma
SH-SY5Y cells (Wang et al., 1996; Peng et al., 1997). However, the cell line also ex-
presses β2 subunits, foreign to bovine chromaffin cells. Furthermore, the affinity I
obtained for dihydro-β-erythroidine is similar to that reported for rat α3β4 receptors
(Xiao et al., 1998). Another possibility is that the low-affinity receptor class represents
the α7 homomeric receptors, which are less sensitive to epibatidine than the hetero-
pentameric neuronal nicotinic receptors (Gerzanich et al., 1995; Delbono et al., 1997).
However, α-bungarotoxin displaced only one sixth of the label when 1 nM [3H]epi-
batidine was used, and it was totally ineffective in displacing 100 pM epibatidine. The
relatively low affinity of methyllycaconitine to the receptors and the micromolar
concentrations required also argue against a major involvement of α7 homomers in
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the two-site binding, but fits better to the data previously obtained with α3β4 recep-
tors (López et al., 1998).
In light of the pre-existing data and my results, the apparent two-site binding proba-
bly reflects different affinity states of the α3β4* receptors. However, the apparent two-
site binding is a mathematical model of the results obtained, and the actual binding of
the label may be, and probably is, more complicated. Therefore, caution is needed in
deducing the real nature of the apparent binding sites. In the brain, the apparent one-
site binding most likely occurs at the α4β2 receptors. The cotinine affinity to the brain
receptors was over an order of magnitude higher than to the chromaffin cell receptors.
The binding of cotinine to brain receptors also explains cotinine effects detected on
brain preparations in vitro (Dwoskin et al., 1999).
Most likely, activation is not the primary means of cotinine affecting cholinergic recep-
tors in vivo. This is supported by the present results that relatively low cotinine con-
centrations inhibit nicotinic responses, while high concentrations are required for re-
ceptor activation. In fact, most nicotinic agonists desensitise their receptors at lower
concentrations than are required for activation (Marks et al., 1996). As the desensiti-
sation is well established in both repeated and continuous exposure of cells to nicotinic
agonists (Boksa and Livett, 1984; Marley, 1988), it may apply to cotinine as well. Data
suggesting such a phenomenon in oocyte-expressed human α7 receptors has been pre-
sented (Briggs and McKenna, 1998). By silencing nicotinic receptors, cotinine may
counteract some of the effects of nicotinic agonists at the concentrations reached with
tobacco or alternative nicotine use, even without detectable stimulation. The
phenomenon may have a role in the clinical effects of cotinine, such as a worsening of
tobacco withdrawal symptoms (Keenan et al., 1994; Hatsukami et al., 1998). However,
the effects of smoking and nicotine replacement therapy may well be secondary to re-
ceptor desensitisation. This is even likely since the concentrations of nicotine reached
upon voluntary administration (Benowitz et al., 1988; Gourlay and Benowitz, 1997)
are insufficient to activate nicotinic acetylcholine receptors, but rather desensitise
them (Marks et al., 1996).
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CONCLUSIONS
1 Bovine adrenal chromaffin cells possess PLD protein and PLD1-like activity that
can be activated by G-protein coupled receptor activators angiotensin II and
bradykinin, and by phorbol ester stimulation of PKC.
2 PLD activation is not necessary for chromaffin cell exocytosis. Neither does PLD
participate in nicotine signalling nor in sustained chromaffin cell responses to an-
giotensin II or bradykinin.
3 Cotinine inhibits nicotinic responses, such as elevation of [Ca++]i, increase in PKC
activity and noradrenaline exocytosis, in bovine adrenal chromaffin cells.
4 Cotinine efficiently stimulates bovine adrenal chromaffin cells, but high concentra-
tions are required. The cotinine-evoked responses include elevation of [Ca++]i, in-
crease in PKC activity, and noradrenaline exocytosis.
5 Cotinine binds to nicotinic binding sites at acetylcholine receptors. The nicotinic
acetylcholine receptor agonism initiates the chromaffin cell responses to cotinine.
6 Cotinine affinity for nicotinic acetylcholine receptors is low, and the cotinine con-
centrations achieved in nicotine consumption are likely to affect the receptor activ-
ity states.
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